Nutzung funktioneller Abhängigkeiten in Tumorzellen zur Entwicklung zielgerichteter Therapien

Schlüsselwörter

Onkogen-Abhängigkeit - synthetische Letalität - zielgerichtete Therapie - translationale Onkologie

Keywords

oncogene addiction - synthetic lethality - targeted therapy - translational oncology

• Literatur

• 1 Azoitei N, Hoffmann CM, Ellegast JM et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012; 209: 697-711
• 2 Barbie DA, Tamayo P, Boehm JS et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112
• 3 Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nat Med 2009; 15: 1149-1152
• 4 Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134
• 5 Fröhling S, Scholl C, Levine RL et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12: 501-513
• 6 Kumar MS, Hancock DC, Molina-Arcas M et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012; 149: 642-655
• 7 Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol 2010; 8: 38
• 8 Puyol M, Martín A, Dubus P et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73
• 9 Scholl C, Fröhling S, Dunn IF et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-834
• 10 Weinstein IB, Begemann M, Zhou P et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997; 3: 2696-2702